
Sarvari V Yellapragada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3957912/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Using wearables to screen motor performance deterioration because of cancer and chemotherapy-induced peripheral neuropathy (CIPN) in adults - Toward an early diagnosis of CIPN. Journal of Geriatric Oncology, 2019, 10, 960-967.	1.0	33
2	HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e143-e146.	0.4	15
3	Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. Cancers, 2021, 13, 3053.	3.7	15
4	The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers, 2021, 13, 843.	3.7	12
5	State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias. Radiologic Clinics of North America, 2016, 54, 581-596.	1.8	11
6	Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor. Leukemia Research Reports, 2015, 4, 1-3.	0.4	10
7	Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. Journal of the National Cancer Institute, 2021, 113, 1084-1093.	6.3	10
8	The detrimental association between fear of falling and motor performance in older cancer patients with chemotherapy-induced peripheral neuropathy. Gait and Posture, 2021, 88, 161-166.	1.4	8
9	Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Case Reports in Hematology, 2015, 2015, 1-5.	0.4	5
10	Significant improvement in overall survival among patients diagnosed with lowâ€risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors. British Journal of Haematology, 2017, 177, 142-144.	2.5	3
11	Survival outcome of veterans with myelodysplastic syndrome (MDS) treated with statins Journal of Clinical Oncology, 2012, 30, e17018-e17018.	1.6	3
12	Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma Journal of Clinical Oncology, 2019, 37, 8033-8033.	1.6	3
13	Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system Journal of Clinical Oncology, 2021, 39, 10507-10507.	1.6	2
14	Differential response to carfilzomib based on initial therapy with bortezomib in multiple myeloma Journal of Clinical Oncology, 2017, 35, e19515-e19515.	1.6	2
15	Treatment Options for Relapsed and Refractory Multiple Myeloma. JAMA Oncology, 2021, 7, 1449-1450.	7.1	1
16	Evaluating the Efficacy and Toxicity of Two Lenalidomide Dose Regimens for the Treatment of Older Relapsed Multiple Myeloma Patients with Co-Morbidities: A Multi-Site Study at the Veteran's Administration Hospitals. Blood, 2015, 126, 5370-5370.	1.4	1
17	Lack of racial disparity in outcome of African American (AA) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (VA) hospitals Journal of Clinical Oncology, 2018, 36, 8033-8033.	1.6	1
18	A Monoclonal Antibody to Lactadherin Inhibits Sickle Red Blood Cell Adhesion to Vascular Endothelial Cells in a Plasma Milieu Blood, 2006, 108, 1236-1236.	1.4	0